Trends in chronic opioid therapy among survivors of head and neck cancer.

ABSTRACT:

Background

Survivors of head and neck cancer (HNC) have increased risk of opioid misuse.

Methods

Using Surveillance, Epidemiology and End-Results-Medicare data, we matched adults ≥66 years diagnosed with HNC 2008-2015 with cancer-free controls. We computed odds ratios (OR) for receipt of chronic opioid therapy (COT, claims for ≥90 consecutive days) for HNC survivors compared to controls each year after matching through 2016.

Results

The cohort of HNC survivors declined from 5107 in the first year after diagnosis to 604 in the sixth year after diagnosis. For 5 years, rates of COT among HNC survivors exceeded that of controls. Differences between survivors and controls declined each year (ORs: year 1, 4.36; year 2, 2.60; year 3, 2.18; year 4, 1.85; and year 5, 1.35; all P-values <.05).

Conclusions

Among older HNC survivors, cancer-associated opioid use in the first years after diagnosis suggests that the benefit of opioids must balance the risk of opioid misuse.

SUBMITTER: Kriplani A 

PROVIDER: S-EPMC8405132 | biostudies-literature |

REPOSITORIES: biostudies-literature